Biotheranostics, Inc., is a leader in helping physicians improve the care of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients.
The company’s Breast Cancer Index® helps oncologists make difficult decisions about extended endocrine therapy for ER+ breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing endocrine therapy.
Its CancerTYPE ID® is the most rigorously validated gene expression test for metastatic patients with diagnostic ambiguity, helping physicians determine optimal site-directed treatment regimens to improve patient outcomes.
Biotheranostics is based in San Diego, CA. Eric Bednarski and Kyle Dempsey represent MVM’s investment in the company and Eric has joined the Board of Directors.